Abcam, ab289728, Anti-VIRMA/KIAA1429 antibody [EPR24279-23] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal VIRMA/KIAA1429 antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Mouse, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24279-23,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:WB, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab289728 is the carrier-free version of
ab271136
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VIRMA also known as KIAA1429 is a protein with an essential role in the RNA N6-adenosine methylation process often referred to as m6A modification. It has a molecular mass around 200 kDa and is expressed widely across various tissues prominently in the brain liver and kidney. As a component of the m6A methylation machinery it associates with other proteins that determine m6A methyltransferase activity.
Biological function summary
This protein plays a significant part in mRNA modification by acting as an important component of the m6A writer complex. It contributes to the regulation of gene expression by modulating mRNA stability and translation. The m6A writer complex which includes METTL3 METTL14 and WTAP often coordinates with VIRMA to ensure proper mRNA methylation affecting cellular processes such as differentiation and proliferation. Its involvement in this complex implies its importance for mRNA metabolism and gene expression regulation.
Pathways
VIRMA significantly impacts the RNA processing and degradation pathways. Within these pathways it interacts with proteins such as METTL3 and METTL14 to influence mRNA splicing and degradation which are vital for cellular homeostasis. Moreover VIRMA is closely linked to the circadian rhythm pathway. It regulates mRNA targets affecting the rhythmic expression of clock genes underlining cellular timing mechanisms.
VIRMA is connected to cancer and metabolic disorders. Alterations in its methylation activity correlate with tumorigenesis and cancer progression particularly in liver cancer. It cooperates with proteins like METTL3 in promoting oncogenic mRNA translation leading to uncontrolled cell growth. Additionally dysregulation of RNA methylation involving VIRMA influences the metabolism contributing to disorders like obesity. This makes it an attractive target for therapeutic strategies aiming to modulate abnormal methylation patterns.